Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins

Cell Death and Differentiation

Volumn 11, Issue SUPPL. 1, 2004, Pages

  Luegmayr, E ^a   Glantschnig, H ^a   Wesolowski, G A ^a   Gentile, M A ^a   Fisher, J E ^a   Rodan, G A ^a   Reszka, Alfred A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apoptosis; HDL; HMGCR; LDL; LDL receptor; Methyl cyclodextrin

Indexed keywords

ACTIN; CASPASE 3; CHOLESTEROL; COLONY STIMULATING FACTOR 1; CYCLODEXTRIN; HIGH DENSITY LIPOPROTEIN; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; PROTEIN S6; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE DISEASE; CELL DIFFERENTIATION; CELL SIZE; CELL SPECIFICITY; CELL STRUCTURE; CELL SURVIVAL; CELL TYPE; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME MECHANISM; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ACID PHOSPHATASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOLIPOPROTEIN A-I; APOPTOSIS; BETA-CYCLODEXTRINS; BONE MARROW CELLS; CALCITRIOL; CARRIER PROTEINS; CASPASE 3; CASPASES; CAVEOLIN 2; CAVEOLINS; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; FIBROBLASTS; GENE EXPRESSION; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; ISOENZYMES; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROFILAMENTS; NIH 3T3 CELLS; OSTEOCLASTS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, LDL; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES; SEX FACTORS; UP-REGULATION;

EID: 4344590941     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401399     Document Type: Article

References (69)

1. Browner WS, Pressman AR, Nevitt MC, Cauley JA and Cummings SR (1993) Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke 24: 940-946
2. Von der Recke P, Hansen MA and Hassager C (1999) The association between low bone mass at the menopause and cardiovascular mortality. Am. J. Med. 106: 273-278
3. Kado DM, Browner WS, Blackwell T, Gore R and Cummings SR (2000) Rate of bone loss is associated with mortality in older women: a prospective study. J. Bone Miner. Res. 15: 1974-1980
4. Boukhris R and Becker KL (1972) Calcification of the aorta and osteoporosis. A roentgenographic study. JAMA. 219: 1307-1311
5. Frye MA, Melton Lj, Bryant SC, Fitzpatrick LA, Wahner HW, Schwartz RS and Riggs BL (1992) Osteoporosis and calcification of the aorta. Bone Miner. 19: 185-194
6. Vogt MT, San Valentin R, Rorrest KY, Nevitt MC and Cauley JA (1997) Bone mineral density and aortic calcification: the study of osteoporotic fractures. J. Am. Geriatr. Soc. 45: 140-145
7. Barengolts El, Berman M, Kukreja SC, Kouznetsova T, Lin C and Chomka EV (1998) Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif. Tissue Int. 62: 209-213
8. Broulik PD and Kapitola J (1993) Interrelations between body weight, cigarette smoking and spine mineral density in osteoporotic Czech women. Endocr. Regul. 27: 57-60
9. Uyama O, Yoshimoto Y, Uamamoto Y and Kawai A (1997) Bone change and carotid atherosclerosis in postmenopausal women. Stroke 28: 1730-1732
10. Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sow H, Chen Q and Chihara K (2002) Plasma lipids and osteoporosis in postmenopausal women. Endocrine J. 49: 211-217
11. Steinberg D, Carew TE, Fielding C, Fogelman AM, Mahley RW, Sniderman AD and Zilversmit DB (1989) Lipoproteins and the pathogenesis of atherosclerosis. Circulation 80: 719-723
12. Witztum JL and Steinberg D (1991) Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88: 1785-1792
13. Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Territo M and Demer LL (1999) Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J. Bone Miner. Res. 14: 2067-2078
14. Diascro Jr DD, Vogel RL, Johnson TE, Witherup KM, Pitzenberger SM, Rutledge SJ, Prescott DJ, Rodan GA and Schmidt A (1998) High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner. Res. 13: 96-106
15. Parhami F and Demer LL (1997) Arterial calcification in face of osteoporosis in ageing: can we blame oxidized lipids? Curr. Opin. Lipidol. 8: 312-314
16. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W and Demer LL (2001) Atherogenic high-fat diet reduces bone mineralization in mice. J. Bone Miner. Res. 16: 182-188
17. Sato T, Morita I and Murota S (1998) Involvement of cholesterol in osteoclast-like cell formation via cellular fusion. Bone 23: 135-140
18. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA and Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373: 231-241
19. Kilsdonk EP, Yancey PG, Stoudt GW, Bangerter FW, Johnson WJ, Phillips MC and Rothblat GH (1995) Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270: 17250-17256
20. Reszka AA, Halasy-Nagy JM, Masarachia PJ and Rodan GA (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 274: 34967-34973
21. Ito M, Amizuka N, Nakajami T and Ozana H (2001) Bisphosphonate acts on osteoclasts independent of ruffled borders in osteosclerotic (ocloc) mice. Bone 28: 609-616
22. Ha H, Kwak HB, Lee SK, Na DS, Rudd CE, Lee ZH and Kim HH (2003) Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. J. Biol. Chem. 278: 18573-18580
23. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA and Reszka AA (2003) MCSF, TNFα and RANK-ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Diff. 10: 1165-1177
24. Glantschnig H, Varga F and Klaushofer K (1996) The cellular protooncogenes c-fos and egr-1 are regulated by prostacyclin in rodent osteoblasts and fibroblasts. Endocrinology 137: 4536-4541
25. Inoki K, Li Y, Zhu T, Wu J and Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657
26. Fogelman AM, Seager J, Edwards PA and Popjak G (1977) Mechanism of induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human leukocytes. J. Biol. Chem. 252: 644-651
27. Osborne TF, Gil G, Goldstein JL and Brown MS (1988) Operator constitutive mutation of 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter abolishes protein binding to sterol regulatory element. J. Biol. Chem. 263: 3380-3387
28. Field FJ, Shreves T, Fujiwara D, Murthy S, Albright E and Mathur SN (1991) Regulation of gene expression and synthesis and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by micellar cholesterolin CaCo-2 cells. J. Lipid Res. 32: 1811-1821
29. Bist A, Fielding PE and Fielding CJ (1997) Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc. Natl. Acad. Sci. USA 94: 10693-10698
30. Uittenbogaard A and Smart EJ (2000) Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J. Biol. Chem. 275: 25595-25599
31. Fujimoto T, Kogo H, Nomura R and Une T (2000) Isoforms of caveolin-1 and caveolar structure. J. Cell Sci. 113 (Part 19) 3509-3517
32. Christian AE, Haynes MP, Phillips MC and Rothblat GH (1997) Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid Res. 38: 2264-2272
33. Parhami F, Garfinkel A and Demer LL (2000) Role of lipids in osteoporosis. Arterioscler. Thromb. Vasc. Biol. 20: 2346-2348
34. Demer LL (2002) Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int. J. Epidemiol. 31: 737-741
35. Burnett JR and Vasikaran SD (2002) Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann. Clin. Biochem. 39 (Part 3): 203-210
36. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA and Demer LL (1997) Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17: 680-687
37. Tintut Y, Saedi B, Saini T, Ariax-Magaloona, Parhami F and Demer LL (2002) Hyperlipidemia enhanced osteoclastic potential of bone-marrow preosteoclasts. J. Bone Miner. Res. 17 (Suppl 1): M261
38. Luegmayr E, Rodan GA and Reszka AA (2002) Lipoproteins/exogenous cholesterol regulate osteoclast formation and survival. J. Bone Miner. Res. 17 (Suppl 1): F241
39. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M and Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949
40. Johnston Jr CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath 3rd H, Gennari C, Christiansen C, Arnaud CD and Delmas PD (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch. Intern. Med. 160: 3444-3450
41. Rogers MJ (2000) Statins: lower lipids and better bones? Nat. Med. 6: 21-23
42. Toledano JE and Partridge NC (2000) Statins: not just for cholesterol? Trends Endocrinol. Metab. 11: 255-256
43. Ferber D (2000) Osteoporosis: cholesterol drugs show promise as bone builders. Science 288: 2297-2298
44. Ylitalo R (2000) Bisphosphonates and atherosclerosis. Gen. Pharmacol. 35: 287-296
45. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M and Demer LL (2002) 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J. Biol. Chem. 277: 14221-14226
46. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL and Phillips MC (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40: 781-796
47. Suc I, Escargueil-Blanc I, Troly M, Salvayre R and Negre-Salvayre A (1997) HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 17: 2158-2166
48. Sugano M, Tsuchida K and Makino N (2000) High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem. Biophys. Res. Commun. 272: 872-876
49. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U and Assmann G (2001) Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276: 34480-34485
50. Matsunaga T, Iguchi K, Nakajima T, Koyama I, Miyazaki T, Inoue I, Kawai S, Katayama S, Hirano K, Hokari S and Komoda T (2001) Glycated high-density lipoprotein induces apoptosis of endothelial cells via a mitochondrial dysfunction. Biochem. Biophys. Res. Commun. 287: 714-720
51. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE and Herz J (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893
52. Parhami F, Watson AD, Dominguez A, Beamer WG, Hama S, Navab M, Drake TA and Wand X (2001) Parallel development of vascular calcification and osteoporosis in hyperlipidemic mice: evidence for the role of lipid oxidation products. J. Bone Miner. Res. 16 (Suppl 1): 1144
53. Ohtani Y, Irie T, Uekama K, Fukunaga K and Pitha J (1989) Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186: 17-22
54. Irie T, Fukunaga K and Pitha J (1992) Hydroxypropylcyclodextrins in parenteral use. I: Lipid dissolution and effects on lipid transfers in vitro. J. Pharm. Sci. 81: 521-523
55. Greenberg-Ofrath N, Terespolosky Y, Kahane I and Bar R (1993) Cyclodextrins as carriers of cholesterol and fatty acids in cultivation of mycoplasmas. Appl. Environ. Microbiol. 59: 547-551
56. Klein U, Gimpl G and Fahrenholz F (1995) Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 34: 13784-13793
57. Gimpl G, Burger K and Fahrenholz F (1997) Cholesterol as modulator of receptor function. Biochemistry 36: 10959-10974
58. Green JM, Zhelesnyak A, Chung J, Lindberg FP, Sarfati M, Frazier WA and Brown EJ (1999) Role of cholesterol in formation and function of a signaling complex involving alphavbeta3, integrin-associated protein (CD47), and heterotrimeric G proteins. J. Cell Biol. 146: 673-682
59. Gupta AK and Rudney H (1991) Plasma membrane sphingomyelin and the regulation of HMG-CoA reductase activity and cholesterol biosynthesis in cell cultures. J. Lipid Res. 32: 125-136
60. Muir LV, Born E, Mathur SN and Field FJ (1996) Lysophosphatidylcholine increases 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene expression in CaCo-2 cells. Gastroenterology 110: 1068-1076
61. Nordskog BK, Reagan Jr JW and St Clair RW (1999) Sterol synthesis is up-regulated in cholesterol-loaded pigeon macrophages during induction of cholesterol efflux. J. Lipid Res. 40: 1806-1817
62. Field FJ, Born E, Murthy S and Mathur SN (2001) Regulation of sterol regulatory element-binding proteins by cholesterol flux in CaCo-2 cells. J. Lipid Res. 42: 1687-1698
63. Fielding CJ and Fielding PE (2001) Caveolae and intracellular trafficking of cholesterol. Adv. Drug Deliv. Rev. 49: 251-264
64. Fuller K, Owens JM, Jagger CJ, Wilson A, Moss R and Chambers TJ (1993) Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J. Exp. Med. 178: 1733-1744
65. Boyle WJ, Simonet WS and Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342
66. Wesolowski G, Duong LT, Lakkakorpi PT, Nagy RM, Tezuka K, Tanaka H, Rodan GA and Rodan SB (1995) Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells. Exp. Cell Res. 219: 679-686
67. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA and Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96: 133-138
68. Halasy-Nagy JM, Rodan GA and Reszka AA (2001) Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29: 553-559
69. Reszka AA, Halasy-Nagy J and Rodan GA (2001) Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 59: 193-202